MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

Search

Ionis Pharmaceuticals Inc

Cerrado

SectorSanidad

68.39 3.92

Resumen

Variación precio

24h

Actual

Mínimo

65.44

Máximo

68.39

Métricas clave

By Trading Economics

Ingresos

270M

124M

Ventas

320M

452M

Margen de beneficios

27.331

Empleados

1,069

EBITDA

294M

150M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+13.31% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

3.7B

10B

Apertura anterior

64.47

Cierre anterior

68.39

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

149 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

Ionis Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

2 oct 2025, 23:30 UTC

Acciones populares

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2 oct 2025, 21:21 UTC

Ganancias

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3 oct 2025, 00:00 UTC

Adquisiciones, fusiones, absorciones

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2 oct 2025, 23:40 UTC

Charlas de Mercado

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2 oct 2025, 23:39 UTC

Charlas de Mercado

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2 oct 2025, 23:29 UTC

Adquisiciones, fusiones, absorciones

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2 oct 2025, 23:29 UTC

Adquisiciones, fusiones, absorciones

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2 oct 2025, 23:29 UTC

Adquisiciones, fusiones, absorciones

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2 oct 2025, 23:00 UTC

Charlas de Mercado

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2 oct 2025, 22:54 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Scales's JV Buyout Lauded by Bull -- Market Talk

2 oct 2025, 22:54 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Global Forex and Fixed Income Roundup: Market Talk

2 oct 2025, 22:46 UTC

Charlas de Mercado

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2 oct 2025, 22:46 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

2 oct 2025, 21:17 UTC

Adquisiciones, fusiones, absorciones

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2 oct 2025, 20:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Energy & Utilities Roundup: Market Talk

2 oct 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

2 oct 2025, 20:49 UTC

Adquisiciones, fusiones, absorciones

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2 oct 2025, 20:00 UTC

Adquisiciones, fusiones, absorciones

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2 oct 2025, 19:20 UTC

Charlas de Mercado

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2 oct 2025, 19:10 UTC

Charlas de Mercado

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2 oct 2025, 19:04 UTC

Charlas de Mercado

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2 oct 2025, 18:46 UTC

Adquisiciones, fusiones, absorciones

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2 oct 2025, 18:46 UTC

Adquisiciones, fusiones, absorciones

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2 oct 2025, 18:46 UTC

Adquisiciones, fusiones, absorciones

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2 oct 2025, 18:45 UTC

Adquisiciones, fusiones, absorciones

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2 oct 2025, 18:45 UTC

Adquisiciones, fusiones, absorciones

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2 oct 2025, 18:44 UTC

Adquisiciones, fusiones, absorciones

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2 oct 2025, 18:44 UTC

Adquisiciones, fusiones, absorciones

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2 oct 2025, 18:44 UTC

Adquisiciones, fusiones, absorciones

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2 oct 2025, 18:43 UTC

Adquisiciones, fusiones, absorciones

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Comparación entre iguales

Cambio de precio

Ionis Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

13.31% repunte

Estimación a 12 Meses

Media 74.56 USD  13.31%

Máximo 116.76 USD

Mínimo 43 USD

De acuerdo con 21 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ionis Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

21 ratings

16

Comprar

5

Mantener

0

Vender

Puntuación técnica

By Trading Central

29.78 / 33.645Soporte y Resistencia

Corto Plazo

Neutral Evidence

Medio plazo

Very Strong Bullish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

149 / 371 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat